市場調查報告書
商品編碼
1103578

止痛藥的全球市場

Analgesics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 578 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球止痛藥的市場規模在分析期間預計將以4.7%的年複合成長率增長,從2022年的488億美元,到2026年達到592億美元。

此外本報告所分析的市場區隔之一的處方箋,在分析期間預測將以4.4%的年複合成長率增長,達到377億美元。

本報告提供全球止痛藥市場相關調查,提供市場趨勢和促進因素,各地各國的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca Plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • Johnson & Johnson
  • Lupin Limited
  • Novartis AG
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

  • 企業簡介:146公司
目錄
Product Code: MCP-5064

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Analgesics Market to Reach $59.2 Billion by 2026

Pain management continues to be one of the most sought-after treatment options for patients within the healthcare arena that underscores the critical significance of analgesics. Analgesics are drugs meant for pain control primarily. The drugs work on the CNS and peripheral nervous system for reducing or blocking pain sensitivity. There are also analgesics which work by preventing creation of pain mediating chemicals in the body. Widely used for treatment of mild to acute pain attributed to several medical conditions, injuries, surgeries and terminal disorders, analgesics have ruled the pain management domain for the past several decades. These medications have provided medical practitioners with an effective option to alleviate pain and help improve quality of life for patients. One of the important growth factors for the market for analgesics worldwide is the aging population. Significant incidence of severe pain disorders, treatment options that are effective, and favorable regulations are the key driving forces of the market. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Amid the COVID-19 crisis, the global market for Analgesics estimated at US$48.8 Billion in the year 2022, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period. Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.9 Billion in 2022, While China is Forecast to Reach $8.2 Billion by 2026

The Analgesics market in the U.S. is estimated at US$15.9 Billion in the year 2022. The country currently accounts for a 32.76% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Growth in these markets are benefiting from increasing incidence of diseases like cancer, arthritis, CVD, and also other acute and chronic diseases which causes severe pain. Cancer pain, neuropathic pain, post-operative pain, and lower back pain represent the important market segments. Increasing incidence of cancer globally is poised to be a key driving force for market growth. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Opioids Segment to Reach $18.4 Billion by 2026

Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$15.9 Billion in 2022, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.

Select Competitors (Total 146 Featured) -

  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca Plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • Johnson & Johnson
  • Lupin Limited
  • Novartis AG
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • MARKET OVERVIEW
  • FOCUS ON SELECT PLAYERS
  • MARKET TRENDS & DRIVERS
  • GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • AUSTRALIA
  • INDIA
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA

IV. COMPETITION

  • Total Companies Profiled: 146